ReviewNature reviews. Disease primers2018
REM sleep behaviour disorder.
Review in Nature reviews. Disease primers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07324330 (Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity), which is not on this map. Cited by 235 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity
Who cites it
235 citing papers in PubMed, 8 syntheses or guidelines pooled it, 463 citations in OpenAlex.
- Effects of trazodone on polysomnographic sleep architecture in patients with depression and sleep disorders: a systematic review and exploratory meta-analysis.Frontiers in psychiatry · 2026Pooled it
- Guidelines for Parkinson's disease management part II: consensus from the movement disorders scientific department of the Brazilian Academy of Neurology - non-motor symptoms.Arquivos de neuro-psiquiatria · 2025Guideline
- Orexin and Sleep Disturbances in Alpha-Synucleinopathies: a Systematic Review.Current neurology and neuroscience reports · 2024Pooled it
- Analysis of biomarkers in speculative CNS-enriched extracellular vesicles for parkinsonian disorders: a comprehensive systematic review and diagnostic meta-analysis.Journal of neurology · 2024Pooled it
- Management of REM sleep behavior disorder: an American Academy of Sleep Medicine clinical practice guideline.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2023Guideline
- Management of REM sleep behavior disorder: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2023Pooled it
- Sleep disturbance in caregivers of individuals with Parkinsonism: a systematic review and meta-analysis.BMJ open · 2022Pooled it
- Melatonin Treatment for Sleep Disorders in Parkinson's Disease: A Meta-Analysis and Systematic Review.Frontiers in aging neuroscience · 2022Pooled it
- The effect of Gua Sha therapy on Parkinson's disease with rapid eye movement sleep behavior disorder: a randomized controlled trial.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Trial
- Effect of Probiotics Supplementation on REM Sleep Behavior Disorder and Motor Symptoms in Parkinson's Disease: A Pilot Study.CNS neuroscience & therapeutics · 2025Trial
- Baseline characteristics of the North American prodromal Synucleinopathy cohort.Annals of clinical and translational neurology · 2023Trial
- Predictors of dream enactment behavior among medical students: The case of the University of Gondar, Ethiopia.PloS one · 2022Trial
- Monocyte markers correlate with immune and neuronal brain changes in REM sleep behavior disorder.Proceedings of the National Academy of Sciences of the United States of America · 2021Trial
- Article
- Fully-automated sleep staging for Parkinson's disease and isolated REM sleep behavior disorder.NPJ digital medicine · 2026Article
- Progression of Motor and Cognitive Functions in Isolated REM Sleep Behavior Disorder: A 7-Year Prospective Matched Cohort Study.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Elevated plasma neurofilament light chain in isolated REM sleep behavior disorder: Associations with neurogenic orthostatic hypotension and implications for phenoconversion.Journal of Parkinson's disease · 2026Article
- Investigation of the "Not Better Explained" Diagnosis Criteria in Sleep Disorder Classifications: A Systematic Content Analysis and Critical Review.Journal of sleep research · 2026Review
- Gut Microbiome in Depression with and without REM Sleep Behavior Disorder.Molecular psychiatry · 2026Article
- Towards automated joint detection in sleep studies: bridging clinical insight and artificial intelligence.Sleep · 2026Article
175 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapid eye movement (REM) sleep behaviour disorder (RBD) is a parasomnia that is characterized by loss of muscle atonia during REM sleep (known as REM sleep without atonia, or RSWA) and abnormal behaviours occurring during REM sleep, often as dream enactments that can cause injury. RBD is categorized as either idiopathic RBD or symptomatic (also known as secondary) RBD; the latter is associated with antidepressant use or with neurological diseases, especially α-synucleinopathies (such as Parkinson disease, dementia with Lewy bodies and multiple system atrophy) but also narcolepsy type 1. A clinical history of dream enactment or complex motor behaviours together with the presence of muscle activity during REM sleep confirmed by video polysomnography are mandatory for a definite RBD diagnosis. Management involves clonazepam and/or melatonin and counselling and aims to suppress unpleasant dreams and behaviours and improve bedpartner quality of life. RSWA and RBD are now recognized as manifestations of an α-synucleinopathy; most older adults with idiopathic RBD will eventually develop an overt neurodegenerative syndrome. In the future, studies will likely evaluate neuroprotective therapies in patients with idiopathic RBD to prevent or delay α-synucleinopathy-related motor and cognitive decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.